Incorporation of excess gadolinium into human bone from medical contrast agents
- 1 January 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 1 (6), 479-488
- https://doi.org/10.1039/b905145g
Abstract
We find anomalously high gadolinium (Gd) concentrations in the femoral head bones of patients exposed to chelated Gd, commonly used as a contrast agent for medical imaging. Gd is introduced in chelated form to protect patients from exposure to toxic free Gd3+ , a calcium antagonist which disrupts cellular processes. Recent studies suggest Gd chelates break down in vivo, and Gd accumulation in tissue is linked to medical conditions such as nephrogenic systemic fibrosis (NSF), acute kidney failure, and in some cases death. We measure Gd and other rare earth element (REE) concentrations in 35 femoral heads by solution based ICP-MS. Gd concentrations in patients with documented exposure to Gd-based contrast agents (n = 13: Gd DTPA-BMA (Omniscan) n = 6; Gd HP-DO3A (Prohance) n = 5; unknown type n = 4) are significantly higher (p < 0.001) than the control group (n = 17). We use our control group to establish the ‘natural’ background level of Gd in human bone (cortical 95% CI: 0.023, 0.041 nmol/g; trabecular 95% CI: 0.054, 0.107 nmol/g). A control group outlier reveals the occurrence of individuals with high concentrations of all REEs, including Gd. Because of this, we calculate Gd anomalies from the concentrations of adjacent REEs and normalize to the control group mean to isolate Gd input from contrast agents. Normalized Gd anomalies, (Gd/Gd*)N, for exposed patients range up to >800 times the ‘natural’ level (95% CI: 124, 460). Our data confirm that Gd, introduced in chelated form, incorporates into bone and is retained for more than 8 years. No difference was observed in bone Gd concentrations and anomalies between patients dosed with Gd DTPA-BMA (Omniscan; n = 6) and Gd HP-DO3A (Prohance; n = 5). Osteoporotic fracture patients exposed to Gd have significantly lower Gd concentrations than osteoarthritis patients (p < 0.001). This indicates different mechanisms of metal incorporation and/or retention in osteoporotic bone tissues, and may signal an increased risk of endogenous Gd release for patients with increased rates of bone resorption (e.g. osteoporosis patients and menopausal, pregnant, and lactating women) who are exposed to Gd-based contrast agents.Keywords
This publication has 56 references indexed in Scilit:
- Gadolinium nephrotoxicity: case report of a rare entity and review of the literatureClinical Nephrology, 2008
- Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injuryBritish Journal of Dermatology, 2007
- Towards the development of a fossil bone geochemical standard: An inter-laboratory studyAnalytica Chimica Acta, 2007
- Long‐term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium‐enhanced MRI scans: case report and implicationsContrast Media & Molecular Imaging, 2007
- Osteoclast and its roles in calcium metabolism and bone development and remodelingBiochemical and Biophysical Research Communications, 2006
- BiomineralsMineralogical Magazine, 2005
- Biomineralization: An OverviewConnective Tissue Research, 2003
- Myocardial viability imaging using Gd‐DTPA: Physiological modeling of infarcted myocardium, and impact on injection strategy and imaging timeMagnetic Resonance in Medicine, 2002
- Gd-DPTA: an i.v. contrast agent for clinical MRIInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1988
- National Estimates of Blood Lead Levels: United States, 1976–1980The New England Journal of Medicine, 1982